It’s in the genes. Meet Auristone! This Singapore-founded biotech startup powers personalized healthcare solutions based on the science of how genes work (aka,  epigenomics).

Now, they’ve just raised a $4M seed!

Investor check. Elev8 led the round. SEEDS Capital joined in, along with existing investor Genedant.

‍

👩🏻‍⚕️ Doctor, doctor!

Their first product, EPI-CALL helps doctors and late-stage cancer patients get clinical insights and figure out the best therapy options.

• It’s a molecular profiling test that helps predict someone’s likelihood of response to different treatment options for cancer.
• It works on top of the genomic information offered by existing providers.

‍

They also offer other products:

• Signomax: RNA Sequencing and Chromatin Immunoprecipitation Sequencing to support research efforts.
• EPI-Tome: a novel biomarker and drug discovery engine driven by epigenomics.

‍

💰 Money matters

They’ll be pushing for more clinical collaborations and market adoption for EPI-CALL.

‍

Oh, and watch out, because they’ll be expanding to South Korea, Japan, and other markets too.